Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.7K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Essential genetic testing in movement disorders - results from a Delphi study.

Parkinsonism & related disorders·2026
Same author

Paroxysmal movement disorders: an update on genetics, mechanisms, and emerging therapeutic strategies.

Current opinion in neurology·2026
Same author

Niemann Pick Type C Presenting as Familial Late-Onset Richardson Syndrome. A Case Series of Four Siblings.

Movement disorders clinical practice·2026
Same author

The Movement Disorder Spectrum of ATP1A3-Related Disorders: Cross-Sectional Analysis and Video Archive of 88 Patients.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Upper Limb Freezing without Gait Freezing in Parkinson's Disease: a Striking Case of a Rare Phenomenon.

Movement disorders clinical practice·2026
Same author

Association of Impulse Control Disorders with Cognitive Performance and Frontal Dysfunction in Patients with Parkinson's Disease.

Journal of clinical medicine·2026
Same journal

Cerebellum crus II cortical thickness as a cognitive brain reserve in Parkinson's disease.

Parkinsonism & related disorders·2026
Same journal

Serious games and virtual reality in Parkinson's disease rehabilitation: A systematic review of randomized controlled trials.

Parkinsonism & related disorders·2026
Same journal

Respiratory-swallow training in Parkinson's disease: Effects of a single session on swallowing safety and efficiency with exploratory comparisons of biofeedback.

Parkinsonism & related disorders·2026
Same journal

Levodopa responsive childhood-onset generalized dystonia with diaphragmatic involvement associated with an SPTBN2 variant.

Parkinsonism & related disorders·2026
Same journal

Approach to a case of Neuro-Gonadal disorder: Perrault syndrome.

Parkinsonism & related disorders·2026
Same journal

Parakinesia in Chorea: Why attribution of intention is misleading.

Parkinsonism & related disorders·2026
See all related articles

Related Experiment Video

Updated: Feb 28, 2026

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

1.9K

Interventions in progressive supranuclear palsy.

Christos Koros1, Maria Stamelou2

  • 1Movement Disorders Clinic, Second Dept. of Neurology, Attikon Hospital, University of Athens, Greece.

Parkinsonism & Related Disorders
|October 14, 2015
PubMed
Summary
This summary is machine-generated.

Progressive supranuclear palsy (PSP) lacks effective treatments. Experimental therapies targeting GSK-3, like davunetide and tideglusib, did not improve patient outcomes in recent trials.

Keywords:
DavunetideGlycogen synthase kinase-3 inhibitorsImmunizationProgressive supranuclear palsyRichardson's syndromeTideglusibTreatment

More Related Videos

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

2.0K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

23.2K

Related Experiment Videos

Last Updated: Feb 28, 2026

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

1.9K
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

2.0K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

23.2K

Area of Science:

  • Neuroscience
  • Neurology
  • Clinical Medicine

Background:

  • Progressive supranuclear palsy (PSP) is a neurodegenerative disease.
  • PSP presents with early falls, slowed vertical saccades, and frontal lobe dysfunction (Richardson's syndrome).
  • No current treatments offer symptomatic relief or neuroprotection for PSP.

Purpose of the Study:

  • To evaluate the efficacy of novel experimental treatments for Progressive Supranuclear Palsy.
  • To assess the role of glycogen synthase kinase-3 (GSK-3) inhibitors in managing PSP symptoms.

Main Methods:

  • Investigated davunetide and tideglusib, both GSK-3 inhibitors.
  • Conducted two recent clinical studies assessing the impact of these agents on PSP patient outcomes.

Main Results:

  • Davunetide and tideglusib failed to demonstrate clinical improvement in PSP patients.
  • Current medical interventions have limited efficacy in managing PSP.

Conclusions:

  • Novel GSK-3 inhibitors have not proven effective for treating Progressive Supranuclear Palsy.
  • Future research directions include targeting tau dysfunction and exploring immunotherapy for PSP.